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Abstract
Aims Todeterminethelong-termhealtheconomicbeneﬁtsassociatedwithlisprovs.regularhumaninsulin(RHI)inUKType
1 diabetic (T1DM) patients using the previously published and validated CORE Diabetes Model.
Methods A literature review designed to capture clinical beneﬁts associated with lispro and T1DM cohort characteristics
speciﬁc to UK was undertaken. Clinical beneﬁts were derived from a Cochrane meta-analysis. The estimated difference
(weighted mean) in glycated haemoglobin (HbA1c)w a s)0.1% (95% conﬁdence interval )0.2 to 0.0%) for lispro vs. RHI.
Severe hypoglycaemia rates for lispro and RHI were 21.8 and 46.1 events per 100 patient years, respectively. Costs
and disutilities were accounted for severe hypoglycaemia rates. All costs were accounted in 2007 £UK from a National Health
Service (NHS) perspective. Future costs and clinical beneﬁts were discounted at 3.5% annually.
Results In the base-case analysis, lispro was projected to be dominant compared with RHI. Lispro was associated with
improvements in quality-adjusted life expectancy (QALE) of approximately 0.10 quality-adjusted life years (QALYs) vs.
RHI (7.60 vs. 7.50 QALYs). Lifetime direct medical costs per patient were lower with lispro treatment, £70 576
vs. £72 529. Severe hypoglycaemia rates were the key driver in terms of differences in QALE and lifetime costs.
Sensitivity analyses with assumptions around time horizon, discounting rates and beneﬁts in terms of glycaemic control
or hypoglycaemic event rates revealed that lispro remained dominant.
Conclusions Our ﬁndings suggest that lispro is likely to improve QALE, reduce frequency of diabetes-related complications
and lifetime medical costs compared with RHI.
Diabet. Med. 26, 803–814 (2009)
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Abbreviations CADTH, Canadian Agency for Drugs and Technologies in Health; CI, conﬁdence interval; CSII,
continuous subcutaneous insulin infusion; CVD, cardiovascular disease; DCCT, Diabetes Control and Complications
Trial; HbA1c, glycated haemoglobin; ICER, incremental cost-effectiveness ratio; IU, International Unit; NICE, National
Institute for Health and Clinical Excellence; NPH, neutral protamine Hagedorn; QALE, quality-adjusted life
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Introduction
Type 1 diabetic (T1DM) patients treated with unmodiﬁed
regularhumaninsulin(RHI)rarelyachievetheirglycaemictarget
and often suffer from postprandial hyperglycaemic excursions,
together with an increased risk of hypoglycaemia in the post-
absorptive period [1]. The shortcomings of RHI lie with its non-
optimalpharmacokineticswhichcannotmimicthephysiological
insulin pattern of non-diabetic individuals and needs to be
administered 30–60 min prior to meals [2]. Evidence from
randomized open-label trials suggests that rapid⁄short-acting
insulin analogues (SAIAs), such as insulin lispro, are more
effective than the conventional RHI in terms of reduced
postprandial plasma glucose excursions [1,3–8] and reductions
inthefrequencyofsevereandnocturnalhypoglycaemia[9–11]as
a result of improved pharmacokinetics [12].
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(NICE) has not published full guidance on the use of SAIAs in
T1DM patients. The current body of evidence [14–17] suggests
that there are clinical beneﬁts associated with the use of SAIAs
and these insulins are playing an increasing role in the treatment
of T1DM in the UK, as reﬂected in a 10.8% increase in
prescriptions from 2005 to 2006 [13]. Beneﬁts of SAIAs in terms
of increased lifestyle ﬂexibility were recognized in a published
clinical guideline from NICE on the diagnosis and management
of T1DM [14]. In addition, it was recommended that SAIAs
shouldbeusedasanalternativetomealtimeRHIinpatientswho
experience problems with nocturnal or late inter-prandial
hypoglycaemia and in those whose blood glucose control does
not require the use of snacks between meals.
In recentyears, SAIAs have received a considerable amount of
attention and there has been a number of publications with
regards to their clinical effects and economic implications [15–
19], including health technology assessments which have
demonstrated that treatment with lispro or aspart signiﬁcantly
reduced glycated haemoglobin (HbA1c) compared with RHI in
T1DM patients [16,17].Funding ofSAIAswould be expected to
increase healthcare budgets [16]. Evidence suggests that the
additional costs incurred by SAIAs will be offset by other
healthcare costs in the ﬁrst 12 months [16]. However, there are
uncertainties surrounding the long-term effects of SAIAs on
complications, mortality and HbA1c because of the lack of high-
quality long-term studies [19]. Furthermore, the long-term
economic impact over patient lifetimes is unknown. There is a
need for additional data on the long-term clinical and economic
outcomes associated with the use of SAIAs and RHI in patients
with T1DM.
The aim ofthisstudy was twofold: ﬁrstto review the available
literature to identify clinical efﬁcacy of SAIAs and published
cohort characteristics representative of T1DM patients within
the UK. Second, to estimate the long-term clinical and economic
outcomes associated with lispro compared with RHI using the
previously published CORE Diabetes Model [20], which
provides estimates of long-term clinical and cost outcomes that
closely match real-life data [21].
Patients and methods
Literature review
Electronic searches for clinical efﬁcacy of SAIAs compared with
RHI and cohort characteristics representative of T1DM patients
within the UK were conducted. Searches were limited to studies
speciﬁc to humans, published in the English language and
between the years of 1990–2008 in the following databases:
PubMed, embase and Ovid medline. Combinations of
descriptors and keywords were used and searches were
performed according to the strategies outlined in the
Supporting Information (Appendix S1). Published articles were
screened based on titles, keywords and abstract. Potentially
relevant articles were then subjected to full-text review.
Additional references cited by the articles were obtained where
appropriate.
CORE Diabetes Model
The CORE Diabetes Model, together with its structure and
data input interfaces, has been described in detail elsewhere
[20]; however, a brief summary is given here. The model
projects long-term health and economic outcomes of a cohort
of diabetic patients. It takes into account baseline cohort
characteristics, history of complications, current and future
management of diabetes and concomitant medications,
treatment effects and changes in physiological parameters
over time. The model is based on a series of sub-models
simulating major complications of diabetes such as angina,
myocardial infarction, heart failure, peripheral vascular
disease, stroke, neuropathy, foot ulcer, amputation, renal
disease and eye disease. Each sub-model is a Markov model
using Monte Carlo simulation incorporating time, state,
time-in state and transition probabilities derived from
published sources. Output data in terms of development of
complications, life expectancy, quality-adjusted life expectancy
(QALE), incremental cost-effectiveness ratio (ICER), annual
costs per patient and cumulative costs per patient can be
projected. The model allows for analyses speciﬁc to type of
diabetes, cohorts, countries and interventions. Thus,
investigation around new interventions can be made and
comparison between management strategies in realistic clinical
settings can be achieved. The outcomes simulated by the
model have been validated previously against other published
epidemiological and clinical studies [21].
Simulation cohort
Baseline cohort characteristics representative of T1DM
patients in the UK were derived from several published
studies based on the results of the literature review [22–31].
Patient demographics, baseline complications and medical
history were sourced from records of primary care physicians
in the UK, The Health Improvement Network (THIN)
database [22]. This includes records for over 2.3 million
active patients and is considered to be representative of the
UK population (and the UK population with T1DM). Baseline
risk factors such as HbA1c, systolic blood pressure,
lipoproteins and triglyceride levels were derived from T1DM
patient records, who attended the diabetes services in
Newcastle upon Tyne, where the data were collected
prospectively over a 9-year period [25]. Racial characteristics
by ethnic group within the UK population were obtained from
the Ofﬁce for National Statistics UK [32]. Long-term
clinical and economic outcomes were calculated using a
simulated population based upon the baseline demographics,
complications and use of concomitant medications. Baseline
cohort characteristics and complications are given in detail in
Table 1.
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ClinicaleffectsoflisproandRHIwerederivedfromtheresultsof
a meta-analysis (the Cochrane review) [17], which examined the
e f f e c t so fS A I A sv s .R H I .I tr e ported an estimated difference
(weighted mean) (WMD) in HbA1c of )0.1% [95% conﬁdence
interval (CI) )0.2 to 0.0] in favour of lispro in comparison with
RHI. In the lispro arm of the base-case simulation, an HbA1c
beneﬁt of )0.1% was applied to the baseline HbA1c of 9.4%
and simulated over patient lifetimes. Signiﬁcant heterogeneity
between trials within the meta-analysis was observed (P = 0.02)
[17].Lispro-speciﬁchypoglycaemiceventrateswerenotreported
in the Cochrane meta-analysis and therefore the reported
hypoglycaemic event rates for SAIAs in general were used
instead. Severe hypoglycaemia episodes were deﬁned as those
requiring third party assistance. However, it was found that, for
the studies included in the Cochrane systematic review, the
deﬁnitionsofseverehypoglycaemiarangedfromthird-partyhelp
to coma and⁄or use of glucagon or glucose. Of the 28 included
studies, the incidence of severe hypoglycaemia ranged from 0 to
247.3(median21.8)episodesper100patientyearsforSAIAsand
from 0 to 544 (median 46.1) for patients treated with RHI.
Median values were computed by dividing the number of severe
hypoglycaemic episodes by the years of exposure and then
multiplying by 100.
The Cochrane systematic review also included the analysis of
overall hypoglycaemic episodes for patients with T1DM treated
with SAIAs vs. RHI. Ten studies were included; however,
heterogeneity between the included studies was acknowledged
where deﬁnitions of hypoglycaemia ranged from less than
2.0 mmol⁄lt o<3 . 9m m o l⁄l with or without symptoms.
Inthemodellinganalysis,minorhypoglycaemiawasdeﬁnedas
eventsnotrequiringthird-partyassistanceorhospitaladmission.
The rates of minor hypoglycaemia were derived indirectly by
calculatingtheoverallhypoglycaemiarates(meaneventsper100
patient years) from the 10 included studies (weighted by the
number of patients in each study). Subsequently, the reported
severe hypoglycaemic event rates were subtracted from the
overall rates to arrive at the minor hypoglycaemia rates of 6790
and 7311 events per 100 patient years for analogues vs. regular
human insulin, respectively.
Forthebase-casemodellinganalysis,theseverehypoglycaemic
event rates of 21.8 events⁄100 patient years vs. 46.1 events⁄100
patient years were used for SAIAs and RHI, respectively. A
conservative approach was taken and minor hypoglycaemic
event rates were not included in the base-case analysis.
P a t i e n t sw e r ea s s u m e dt or e m a i no nt h es a m et r e a t m e n t
regimens throughout the simulation. After the initial beneﬁt
()0.1%) was applied in the lispro arm, HbA1c was assumed to
follow a progression in both arms based on data from the
Diabetes Control and Complications Trial (DCCT) [34]. In the
absence of long-term data, hypoglycaemic event rates in both
treatment groups were assumed to remain constant over the
course of the simulation. It was also conservatively assumed that
severehypoglycaemiceventsdidnotresultinfatalitiesinT1DM,
butaffectedthequalityoflife(asaresultofeventdisutilities)and
costs.
Cohort parameters of typical T1DM patients in the UK, such
as age, duration of diabetes, baseline HbA1c and complications,
were sourced from cross-sectional and observational studies and
regional data as opposed to randomized controlled studies. In
this manner, bias relating to patient selection in randomized
studiesisminimized.TherationaleforusingHbA1cbeneﬁtsfrom
a meta-analysis was that clinical effects of SAIAs were drawn
from studies with different designs and different patient charac-
teristics. This would avoid any bias from one particular study.
Costs
Current prices of insulin lispro (Humalog), RHI (Humulin R)
and basal neutral protamine Hagedorn (NPH) insulin (Humulin
Table 1 Baseline characteristics, complications, concomitant
medications and management of patients in the simulated cohort
Patient demographics Mean sd References
Sex (% male) 53.4 — [22]
Mean age (years) 37.8 — [22]
Duration of diabetes (years) 10.4 — [22]
BMI (kg⁄m
2) 25.6 — [22]
Ethnic origin (%)
Caucasian 93.5 — [32]
Black 2 — [32]
Hispanic 0 — [32]
Native American 0 — [32]
Asian 4.5 — [32]
Risk factors
Glycated haemoglobin
(HbA1c) (%)
9.4 2.10 [25]
Systolic blood pressure (mmHg) 132 21.00 [25]
Total cholesterol (mmol⁄l) 5.4 — [25]
High-density lipoprotein
cholesterol (mmol⁄l)
1.5 — [25]
Low-density lipoprotein
cholesterol (mmol⁄l)
3.2 — [25]
Triglycerides (mmol⁄l) 1.2 — [25]
Proportion of smoker (%) 16.4 — [25]
Pre-existing complications
Myocardial infarction (%) 1.7 [22]
Peripheral vascular disease (%) 1.6 [22]
Stroke (%) 2.2 [22]
Heart failure (%) 0.5 [22]
Microalbuminuria (%) 20 [25]
Background diabetic
retinopathy (%)
27.46 [25]
Neuropathy (%) 9.88 [25]
Patient management
Taking aspirin (%) 4.3 [26]
Taking statins (%) 17.8 [27]
Taking ACE-I (%) 14.6 [28,29]
Screened for retinopathy (%) 63.2 [31]
Screened for renal disease (%) 60 [30]
ACE-I, angiotensin converting enzyme inhibitor;
BMI, body mass index; sd, standard deviation.
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(MIMS) [35]. The costs of insulins were based on weighted
averages of the main insulin products. For the base-case, the
annual costs of insulins were calculated based on the reported
end-of-trialdosesinastudyofpatientswithadiagnosisofT1DM
for more than 2 years on established basal–bolus regimens
aiming for tight glucose control, comparing two treatment
arms, insulin lispro plus basal NPH insulin [32.25 plus
20.25 International Units (IU)] vs. RHI plus basal NPH insulin
(32.25 plus 20.25 IU) in the UK [33]. The annual costs of
treatment were estimated to be £786.83 in the lispro arm and
£775.44 in the RHI arm. Costs associated with self-monitoring
of blood glucose (SMBG) were also included. Diabetes and UK-
speciﬁc direct medical costs incorporating pharmacy costs and
costsofcomplicationswerederived frompublishedsources [36–
44] (see also Supporting Information, Appendix S2). All costs
were expressed in 2007 £UK. Where costs were taken from
earlier published literature, they were inﬂated to 2007 values
using the appropriate UK consumer price indices, accounted
from a third-party healthcare payer, National Health Service
(NHS) perspective and hence indirect costs were not considered.
Health state utilities
Estimatesofhealth-relatedqualityoflifeutilitiesofpatientswith
diabetes(utilityweightsthatareusedtorepresentpreferencesfor
health states) corresponding to myocardial infarction, ischaemic
heart disease, stroke, heart failure, amputation and blindness
were derived from the UK Prospective Diabetes Study (UKPDS)
[45]. Other utilities were supplemented by other published
sources [46–50].
Discounting and time horizon
Futurecostsandhealthbeneﬁtswerediscountedatarateof3.5%
per annum as recommended by NICE, UK [51]. A time horizon
of 50 years was used in the base-case analysis. The simulations
aimed to capture death of all patients in the simulated cohort
within 50 years and to project long-term complications with
their associated costs and consequently the impact on life
expectancy and quality of life over patient lifetimes.
Sensitivity analyses
Sensitivity analyses were performed around the assumptions in
the base-case analysis. Key parameters were varied over a range
of possible scenarios, assessing their impact on health economic
outcomes. We investigated the impact of the time horizon by
varyingthetimebetween0and30 years(herewereportvaluesat
5, 10, 15, 20, 25 and 30 years). Discount rates for costs and
health outcomes were applied at 0 and 7% per annum.T h e
impact of changes in HbA1c on long-term clinical and economic
beneﬁts was assessed by applying no change in HbA1c and
)0.2% change for the insulin lispro arm (in line with the upper
andlower95%CIfromtheCochranemeta-analysis[17]),which
spans the range of values reported in another recent meta-
analysis published by the Canadian Agency for Drugs and
TechnologiesinHealth,WMD)0.09%,95%CI)0.16to)0.01
[16]. The impact of a lower baseline HbA1c of 6.3%, derived
from a UK-speciﬁc lispro study [33], on the long-term clinical
and economic outcomes was also assessed. The inﬂuence of
hypoglycaemic event rates was determined. In one sensitivity
analysis, severe hypoglycaemic event rates of lispro were applied
to both treatment arms (i.e. assumed no difference). In another
sensitivity analysis, minor hypoglycaemic event rates were
included in addition to severe hypoglycaemia rates. The lispro
regimenwasassociatedwith6790.13events⁄100patientyearsin
comparison with 7311.75 events⁄100 patient years for RHI
(difference of 521.62 events⁄100 patient years). To assess the
impact of insulin dose on the economic outcomes, the same
treatmenteffectsasinthebase-casewereassumed,buttreatment
costs were analysed based on varying dosages. First, it was
assumed that patients received 54 IU⁄day for each of the insulin
treatments;i.e.54 IU⁄dayforprandialinsulinplus54 IU⁄dayfor
basalinsulin (total108 IU⁄day for eachtreatmentarm). Second,
a conservative approach from a modelling perspective was
assumed, the insulin lispro dose was increased to 54 IU⁄day and
all other insulins remained the same as in the base-case. Third, it
was assumed that there were dosage beneﬁts associated with
lispro treatment, thus RHI was set to 54 IU⁄day and all other
insulins remained the same as those of the base-case.
Statistical methodology
For each analysis in the base-case and sensitivity analyses,
1000 · 1000 iterations were performed based on the simulation
cohort. Using a non-parametric bootstrapping approach, 1000
mean costs and effect pairs (each of 1000 iterations) were
calculated for each treatment group [52]. The joint density of
meanincrementalcostsandincrementaleffectiveness(intermsof
quality-adjusted life expectancy) for lispro vs. RHI were plotted
as a scatter plot on a cost-effectiveness plane. The uncertainty
surrounding the cost-effectiveness of lispro vs. RHI was assessed
through a range of willingness-to-pay thresholds. From this,
cost-effectiveness acceptability curves were generated for the
base-case and the sensitivity analysis assessing the impact of
severe hypoglycaemia.
Results
Literature review
Cohort characteristics typical of T1DM adult patients in the UK
resulting from the literature search are deﬁned in Patients and
methods.
Treatment effects of short-acting insulin analogues
Fromtheliteraturesearch2284articleswereidentiﬁed.Ofthese,
2232 articles were excluded because they were reviews,
pharmacodynamic or pharmacokinetic studies, non-
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diabetes or trials with less than 4 weeks’ study period. From 52
potentially relevant articles, six studies were excluded because
they were of diabetes in infants and young patients. Forty-four
studies were selected [1,3,4,6–8,10,33,53–88], reporting the
clinicalbeneﬁtsassociatedwiththetreatmentofSAIAsinT1DM
patients. We also identiﬁed two meta-analyses [16,17]
containing relevant data for the inclusion in the literature
review and the cost-effectiveness analysis. They reported clinical
outcomes associated with SAIAs in comparison with RHI in
patients with Type 1, Type 2 and gestational diabetes. Their
outcome measures were HbA1c, blood glucose levels,
hypoglycaemia, adverse events, mortality and quality of life.
Of the 44 studies identiﬁed, 29 showed beneﬁts in terms of
HbA1c reductions from baseline associated with SAIAs
compared with RHI [1,3,6,33,53,55,58–61,63,67,69–
77,79,82–88]. Thirteen of these 29 estimated differences in
favour of SAIAs that were statistically signiﬁcant at the 5% level
[3,6,53,55,67,69,71,75,82,83,85,86,88]. The magnitude of
differences in HbA1c between SAIAs and RHI was relatively
small; mean difference between treatments in HbA1c reductions
ranged from )0.01 to )0.77%. Fourteen studies demonstrated
that SAIAs compared with RHI resulted in improved
postprandial glucose excursion control, but had no effect on
HbA1c or were not associated with signiﬁcant beneﬁts in
reducing HbA1c [4,7,8,10,54,56,57,62,64–66,78,80,81]; one
study showed signiﬁcantly higher treatment satisfaction and
treatmentﬂexibilityscoresforT1DMtreatedwithlisprovs.RHI
[68].
Twenty-three studies demonstrated that SAIAs were
associated with lower hypoglycaemia rates [3,4,7,8,10,33,
53,55,60,63,64,71,73–75,77,79–81,85–88]. There were mean
differences in endpoint hypoglycaemic event rates (not all
statistically signiﬁcant), which ranged from )0.1 to )4.1
episodes per patient per month in favour of SAIAs when
compared with RHI. Studies speciﬁc to lispro demonstrated
that injections of lispro immediately before meals lowered
postprandial serum glucose excursions compared with patients
treated with RHI [4,8]. Furthermore, treatment with lispro
resulted in lower hypoglycaemic event rates, with the largest
improvement during night-time [4,8,33]. Importantly, patients
with T1DM treated with lispro were also reported to have
achieved signiﬁcantly lower HbA1c [53]. Clinical beneﬁts were
more pronounced with the use of continuous subcutaneous
insulin infusion (CSII) [6,67,69,71,73,75]; ﬂuctuations in
postprandial blood glucose levels were signiﬁcantly reduced.
HbA1c was signiﬁcantly lower and the insulin requirement was
slightly but signiﬁcantly lower with lispro.
Tworecentmeta-analyses[16,17]gaveaccountsoftheclinical
effectiveness of SAIAs vs. RHI. The Cochrane review [17]
published ﬁndings based on meta-analysis performed on
randomized controlled trials with an intervention duration of
at least 4 weeks. The reviewers identiﬁed 49 potential
randomized controlled trials, but excluded 24 studies for
reasons such as the absence of baseline HbA1c or follow-up
data, studies performed on pre-pubertal children, adolescents
and women with gestational diabetes. Sixteen studies compared
l is provs .RH I;theH bA 1cchange from baseline was greaterwith
lispro than RHI in T1DM patients. The WMD of HbA1c was
)0.1% (95% CI )0.2 to 0.0) in favour of lispro. Subgroup
analysesofstudiesofdifferenttypesofinterventionssuggestthat
using CSII was more effective compared with intensive insulin
therapy (IIT). The WMD was )0.2% (95% CI )0.3 to )0.1)
comparing insulin analogues to RHI. Furthermore, SAIAs were
associated with greater beneﬁts in terms of severe and minor
hypoglycaemic event rates.
Findings from the Cochrane review are supported by a
second meta-analysis published by the Canadian Agency for
Drugs and Technologies in Health (CADTH) [16]. The
analysis included 47 studies on T1DM, 34 of which
described the use of lispro, in which signiﬁcantly greater
reductions in HbA1c levels with lispro compared with RHI
were reported. The WMD was )0.09% (95% CI )0.16 to
)0.01). In addition, the difference was more pronounced in
patients receiving CSII; WMD was )0.28% (95% CI )0.45 to
)0.12). However, the overall and severe hypoglycaemic event
rates were similar with the two treatments, but the occurrence
of nocturnal hypoglycaemia was less frequent with lispro in
comparison with RHI.
The WMD of HbA1c from the Cochrane meta-analysis was
similar to that of the CADTH meta-analysis ()0.1 and )0.09%,
respectively); the upper and lower 95% CI from the Cochrane
meta-analysis also spans those reported in the CADTH meta-
analysis ()0.2 to )0.0 and )0.16 to )0.01, respectively). For
these reasons, treatment effects, WMD of HbA1c,f r o mt h e
Cochrane meta-analysis were employed in our base-case and
sensitivity analyses.
CORE Diabetes Model simulation
Long-term clinical outcomes
Long-term projections of treatment with lispro vs. RHI in a
‘typical’ UK T1DM cohort and based on treatment effects from
theCochranemeta-analysisindicatedthattreatmentwithinsulin
lispro was associated with improvements in life expectancy and
Q A L E( d i s c o u n t e db y3 . 5 %per annum). In the base-case
simulation, mean discounted life expectancy increased by
0.06 years and the mean QALE increased by 0.105 quality-
adjusted life years (QALYs) with lispro compared with RHI
(Table 2). Higher severe hypoglycaemic event rates in the RHI
arm had a notable impact on patients’ quality of life.
The cumulative incidence of diabetes-related complications
such as eye disease, renal complications and cardiovascular
diseases (CVDs) were projected to be lower during treatment
with lispro in comparison with RHI (Table 3). In addition,
lispro was projected to delay time of onset of most diabetes-
related complications (Table 4). The mean time to onset
of any diabetes-related complication was 0.45 years for
lispro and 0.43 years for RHI (an estimated difference of
7.3 days).
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Treatment with lispro was associated with lower direct medical
costs over patients’ lifetimes compared with RHI (£70 576 vs.
£72 529 per patient, respectively). The breakdown of costs
demonstrated that the key driver for the difference in direct
medical costs (£1953 per patient) was the higher severe
hypoglycaemic event rates in the RHI arm (Table 5). Overall
costs of complications during patient lifetimes were marginally
lower in lispro for CVD and eye and foot complications. Lispro
was projected to be a dominant intervention to RHI.
Anincrementalcost-effectivenessscatterplotwasgeneratedby
plotting the 1000 mean costs and effect pairs (QALE) for lispro
vs. RHI (Fig. 1). The ﬁgure shows that most points were in the
south-eastquadrantoftheplane,indicatingthedominantnature
of lispro (increased effectiveness and lower overall costs). The
likelihood of lispro being considered cost-effective was
determined for a range of acceptability ratios. For the base-case
scenario, there was a probability of 83.9% that lispro will be
cost-effective at a threshold of £30 000 (Fig. 2, solid curve).
Table 2 Summary of base-case analysis: clinical and economic outcomes of treatments with insulin lispro vs. regular insulin
Description of outcome Lispro Regular insulin Difference
Life expectancy (years) 11.90 (0.179) 11.844 (0.167) 0.06
Quality-adjusted life expectancy (years) 7.601 (0.117) 7.497 (0.107) 0.105
Lifetime direct medical costs (£) 70 576 (1774) 72 529 (1793) )1953
ICER based on life expectancy Dominant
ICER based on quality-adjusted life expectancy Dominant
ICER, incremental cost-effectiveness ratio.
Values shown are means with standard deviation in parentheses.
All costs and clinical outcomes are discounted at 3.5% per annum.
Table 4 Summary of the mean time to onset of complications
Complication
Time to onset of
complications
(years)
Lispro
Regular
insulin Difference
Any complications 0.45 0.43 0.02
Background retinopathy 3.01 2.86 0.15
Proliferative retinopathy 12.24 12.05 0.19
Microalbuminuria 5.02 4.93 0.09
Gross proteinuria 8.27 8.08 0.19
End-stage renal disease 15.69 15.58 0.11
First event ulcer 13.63 13.49 0.14
Amputation 16.26 16.13 0.13
Neuropathy 3.46 3.34 0.12
Peripheral vascular disease 15.98 15.83 0.15
Congestive heart failure 15.98 15.87 0.11
Angina 16.44 16.36 0.08
Myocardial infarction 15.92 15.78 0.14
Stroke 16.79 16.68 0.11
Cataract 15.99 15.88 0.11
Macular oedema 12.79 12.62 0.17
Severe vision loss 14.60 14.47 0.13
Time to onset of diabetes-related complications of the
base-case.
Values expressed are means.
Table 3 Cumulative incidence of diabetes-related complications and
adverse events of base-case analysis
Complication
Cumulative incidence
diabetes-related
complications (%)
Lispro
Regular
insulin Difference
Background diabetic
retinopathy
83.16 (1.50) 83.92 (1.42) )0.76
Proliferative diabetic
retinopathy
32.11 (1.49) 33.28 (1.46) )1.17
Macular oedema 39.67 (1.57) 40.10 (1.53) )0.43
Severe vision loss 25.30 (1.35) 25.76 (1.34) )0.46
Cataract 12.11 (1.02) 12.00 (1.02) 0.11
Microalbuminuria 75.50 (1.91) 75.83 (2.05) )0.33
Gross proteinuria 67.67 (1.76) 68.45 (1.91) )0.78
End-stage renal
disease
30.76 (1.61) 30.95 (1.62) )0.19
Nephropathy-related
death
28.48 (1.48) 28.64 (1.46) )0.16
Ulcer 47.12 (1.57) 47.19 (1.55) )0.07
Recurrent ulcer 65.37 (4.29) 66.01 (4.46) )0.64
Amputation 14.25 (1.33) 14.35 (1.23) )0.1
Recurrent
amputation
7.09 (1.17) 7.03 (1.04) 0.06
Neuropathy 89.30 (1.03) 89.52 (1.02) )0.22
Coronary heart
failure death
9.99 (0.97) 9.80 (0.92) 0.19
Coronary heart
failure event
23.84 (1.46) 23.65 (1.33) 0.19
Peripheral vascular
disease
15.90 (1.08) 16.31 (1.14) )0.41
Angina 8.61 (0.91) 8.40 (0.87) 0.21
Stroke death 3.82 (0.63) 3.85 (0.63) )0.03
Stroke event 8.20 (0.89) 8.14 (0.86) 0.06
Myocardial
infarction death
20.00 (1.29) 20.18 (1.28) )0.18
Myocardial
infarction event
31.70 (1.45) 32.09 (1.47) )0.39
Severe hypoglycaemia 7.59 (0.18) 14.20 (0.32) )6.61
Incidence expressed as a mean percentage with
standard deviation in parentheses.
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Sensitivity analyses revealed that results of the simulation were
mostsensitivetochangesinhypoglycaemiceventrates(Table 6).
When no difference in severe hypoglycaemia rates was applied,
lispro was associated with a beneﬁt in terms of mean quality-
adjusted life expectancy of approximately 0.034 QALYs vs.
RHI, compared with a beneﬁt of 0.105 QALYs in the base-case.
Costsavingswithlisprowerealsoreduced.Themeansavingover
a patient’s lifetime was approximately £173, assuming no
difference in severe hypoglycaemia (compared with £1953 in
the base-case). The uncertainty of lispro being considered cost-
effective at a threshold of £30 000 was also demonstrated in the
cost-effectiveness acceptability curve for this scenario (Fig. 2,
dashed curve). When beneﬁt in severe hypoglycaemia associated
with lispro was abolished, the resulting probability that lispro
will be cost-effective was 59.1%. Accordingly, there was an
uncertainty of 40.9% that lispro will not be cost-effective.
Capturing minor hypoglycaemic events in the analysis notably
increased the improvement in quality-adjusted life expectancy
associated with lispro. In this scenario, lispro treatment was
projected to improve mean quality-adjusted life expectancy by
approximately 0.355 QALYs vs. RHI. As minor hypoglycaemic
events were conservatively assumed not to incur costs from a
healthcare payer perspective, capturing minor hypoglycaemic
events in the simulation did not alter lifetime direct costs.
Other sensitivity analyses indicated that the lispro treatment
regimen remained dominant at shorter time horizons, even
although the magnitude of clinical and cost beneﬁts was
reduced. Variation in discount rates had little inﬂuence on the
overall conclusions from the analysis. Varying the HbA1c
beneﬁt associated with lispro between the 95% conﬁdence
intervals reported in the Cochrane meta-analysis did not
change relative outcomes: lispro remained dominant to RHI.
Similarly, reducing mean baseline HbA1c in the simulation
cohort to 6.3% (base-case value 9.4%) had little impact on
the relative results. Varying assumptions around the insulin
doses for the calculation of pharmacy costs did not alter the
relative outcomes of the base-case analysis. Assuming 54 IU
per day in all insulins (total daily dose of 108 IU for each
basal–bolus regimen), the lispro regimen remained cost saving
by approximately £1835 vs. RHI over patients’ lifetimes.
Increasing the daily dose of only lispro to 54 IU notably
Table 5 Breakdown of lifetime direct medical costs per patient
Description of cost
Breakdown of
direct costs (£)
Difference Lispro
Regular
insulin
Total costs 70 576 72 529 )1953
Treatment costs 9810 9623 187
Management costs 1375 1372 3
Cardiovascular disease costs 5645 5695 )50
Renal disease costs 26 912 26 844 68
Diabetic foot and
neuropathy costs
22 542 22 714 )172
Eye disease costs 2034 2048 )14
Hypoglycaemia costs 2258 4233 )1975
Breakdown of total lifetime costs per patient of the base-case;
values shown are means.
–12 000
–10 000
–8000
–6000
–4000
–2000
0
2000
4000
6000
8000
10 000
–0.4 –0.2 0.0 0.2 0.4 0.6 0.8
Incremental quality-adjusted life expectancy (QALYs)
I
n
c
r
e
m
e
n
t
a
l
 
c
o
s
t
s
 
(
£
)
FIGURE 1 Incremental cost-effectiveness ratio scatter plot for lispro vs. regular insulin. Base-case analysis incremental cost-effectiveness ratio scatter plot of
1000 values of mean incremental costs plotted against mean incremental effectiveness (quality-adjusted life years gained). The scatter plot was generated
for Type 1 diabetes patients treated with a basal–bolus regimen of lispro vs. regular human insulin. The majority of incremental cost–effect pairs liei nt h e
south-east quadrant, indicating dominance for lispro vs. regular human insulin, where lispro was projected to be more effective and cost saving.
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FIGURE 2 Cost-effectiveness acceptability curves for lispro vs. regular human insulin. Curve in solid line shows cost-effectiveness acceptability curve for
basal–bolus regimens of lispro vs. regular human insulin for the base-case analysis. The acceptability curve demonstrates the likelihood of lispro being
consideredcost-effectiveforarangeofacceptableceilingratios.Thereisaprobabilityof83.9%thatlisprowillbecost-effectivecomparedwithregularhuman
insulin at a threshold of £30 000. In a univariate sensitivity analysis where severe hypoglycaemia rates for both treatment arms were assumed to be
identical (curve in dashed line), the resulting curve demonstrates that there is a 59.1% probability that lispro will be cost-effective compared withr e g u l a r
human insulin at a threshold of £30 000.
Table 6 Summary of sensitivity analyses comparing lispro vs. regular insulin
Assumption
Quality-adjusted life expectancy (QALYs) Lifetime direct costs per patient (£)
ICER⁄£
per QALY
gained Lispro
Regular
insulin Difference Lispro
Regular
insulin Difference
Base-case 7.601 (0.117) 7.497 (0.107) 0.105 (0.154) 70 576 (1774) 72 529 (1793) )1953 (2508) Dominant
5-year time horizon 2.909 (0.024) 2.885 (0.025) 0.025 (0.035) 19 562 (940) 20 229 (950) )667 (1354) Dominant
10-year time horizon 4.807 (0.053) 4.756 (0.052) 0.051 (0.071) 35 613 (1398) 36 899 (1385) )1285 (1997) Dominant
15-year time horizon 6.054 (0.076) 5.978 (0.075) 0.075 (0.106) 48 655 (1570) 50 100 (1535) )1445 (2216) Dominant
20-year time horizon 6.830 (0.095) 6.743 (0.085) 0.038 (0.185) 57 988 (1630) 59 835 (1660) )1846 (2232) Dominant
25-year time horizon 7.278 (0.102) 7.178 (0.107) 0.100 (0.141) 64 561 (1721) 66 289 (1736) )1728 (2455) Dominant
30-year time horizon 7.493 (0.101) 7.388 (0.114) 0.105 (0.155) 68 067 (1830) 70 162 (1898) )2095 (2608) Dominant
0% HbA1c change
applied for lispro
7.567 (0.127) 7.497 (0.107) 0.071 (0.168) 70 891 (1708) 72 529 (1793) )1638 (2414) Dominant
)0.2% HbA1c change
applied for lispro
7.661 (0.121) 7.497 (0.107) 0.165 (0.159) 70 735 (1842) 72 529 (1793) )1794 (2529) Dominant
0% discount rate 10.981 (0.207) 10.808 (0.192) 0.172 (0.273) 112 330 (2988) 115 059 (2919) )2729 (4074) Dominant
7% discount rate 5.688 (0.075) 5.618 (0.069) 0.071 (0.100) 48 988 (1304) 50 449 (1345) )1461 (1899) Dominant
Baseline HbA1c of 6.3% 9.323 (0.137) 9.196 (0.14) 0.127 (0.197) 68 434 (2230) 70 384 (2223) )1949 (3137) Dominant
54 IU⁄day for all of
insulin treatments
7.601 (0.117) 7.497 (0.107) 0.105 (0.154) 75 511 (1789) 77 345 (1807) )1835 (2525) Dominant
54 IU⁄day for lispro 7.601 (0.117) 7.497 (0.107) 0.105 (0.154) 72 497 (1779) 72 529 (1793) )32 (2511) Dominant
54 IU⁄day for
regular insulin
7.601 (0.117) 7.497 (0.107) 0.105 (0.154) 70 576 (1774) 74 346 (1798) )3770 (2511) Dominant
No difference in
severe hypoglycaemia
7.601 (0.117) 7.567 (0.127) 0.034 (0.159) 70 576 (1774) 70 749 (1708) )173 (2465) Dominant
With minor
hypoglycaemic
event rates applied
3.673 (0.062) 3.318 (0.052) 0.355 (0.079) 70 576 (1774) 72 529 (1793) )1953 (2508) Dominant
HbA1c, glycated haemoglobin; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years.
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Conversely, increasing the daily dose of RHI to 54 IU
increased the cost saving with lispro to £3770.
Discussion
In the present study, we conducted a literature review and
performed a modelling analysis designed to estimate the long-
term implications of basal–bolus therapy with insulin lispro
vs. RHI in a population representative of T1DM patients in
the UK. The literature review indicated that SAIAs, such as
lispro, are associated with fewer postprandial glycaemic
excursions, small improvements in HbA1c and notable
beneﬁts in terms of hypoglycaemia compared with RHI.
Based on these short-term ﬁndings, long-term projections
using a previously validated model of diabetes indicated that,
compared with mealtime RHI, mealtime insulin lispro
dominates (more effective and less costly) where the
majority of the plotted cost-effectiveness ratios are situated
in the south-east quadrant of the plane. Furthermore, the cost-
effectiveness acceptability curve showed that there was an
estimated probability of 83.9% that lispro will be considered
cost-effective at a willingness-to-pay threshold of £30 000.
Mealtime insulin lispro is likely to improve life expectancy
marginally and quality-adjusted life expectancy, and reduced
complication rates and direct medical costs when used as part
of a basal–bolus regimen in the UK. These ﬁndings are based
on the most appropriate data currently available. Sensitivity
analysis suggested that these conclusions were robust across
variation in a number of key input parameters, including
HbA1c change, baseline HbA1c and insulin doses (assuming
comparable efﬁcacy). Severe hypoglycaemic event rates were a
key driver of outcomes. However, even conservatively
assuming no beneﬁt in terms of hypoglycaemia with the
insulin lispro regimen, mealtime lispro was still projected to
improve quality-adjusted life expectancy and reduce costs in
UK patients with T1DM vs. RHI. When considering NICE’s
cost-effectiveness threshold range of £20 000–£30 000 per
QALY gained, mealtime insulin lispro in combination with
basal insulin is likely to be considered an attractive therapy,
where the projected ICER for lispro therapy was better than
NICE’s acceptable threshold.
A potential shortcoming of the present analysis lies in the
inherent uncertainty in making long-term projections based on
short-term trial data. We attempted to minimize this uncertainty
as far as possible by (i) selecting treatment effect data from a
meta-analysistoavoidanybiasfromoneparticularstudyand(ii)
using a model of T1DM that has been externally validated
against real-world clinical and epidemiological data. Whilst this
approach may minimize the uncertainty around the projections
reportedhere,itshouldbeacknowledgedthatthesedataarenota
substitute for real-life, long-term clinical follow-up data.
However, in the absence of long-term trial data, model
projections have become an acceptable alternative for a
number of health technology assessment bodies around the
world [including NICE, CADTH, Scottish Medicines
Consortium (SMC) and Pharmaceutical Beneﬁts Advisory
Committee (PBAC)].
In the absence of long-term clinical data on the relative effects
of mealtime lispro vs. RHI, it was assumed that the clinical
beneﬁts on HbA1c and hypoglycaemic event rates would be
maintainedoverthedurationofthemodelsimulation (i.e.whilst
HbA1c followed a natural creep in both arms, the 0.1%-point
beneﬁt with lispro was maintained over the long term). This
assumption, that HbA1c beneﬁts can be maintained long term
and hypoglycaemic event rates remain relatively constant, are
supported by data from the DCCT [34].
The analysis was designed to analyse the long-term
outcomes of treatment in a UK-speciﬁc T1DM population.
On completion of the literature review, it became clear that
this created two challenges. The ﬁrst was that there was no
single published data source that provided a complete list of
cohort that could be used in the modelling analysis. The
cohort used in the simulation is a composite, based on data
from THIN database, as this source offered the largest cross-
sectional sample of T1DM patients currently published [22].
These data were complemented from other UK-speciﬁc
registry or database populations rather than clinical trial
populations, which are often highly selected. Second, in the
modelling simulation, treatment effects used were based on
the results of the Cochrane meta-analysis [17]. As such, the
treatment effects are based on data from a number of
different studies in a number of different populations. Indeed,
studies comparing lispro and RHI showed signiﬁcant
heterogeneity (P = 0.02). As a result, there is a degree of
uncertainty around whether one would expect to see
comparable treatment effects on HbA1c and hypoglycaemic
event rates in a ‘typical’ UK T1DM population. Importantly,
however, one-way sensitivity analysis abolishing the HbA1c
beneﬁt or the hypoglycaemia beneﬁt associated with lispro
both resulted in lispro remaining dominant to RHI.
Moreover, given the conservative approach used in the base-
case analysis, whereby minor hypoglycaemic event rates were
not incorporated, the present base-case may underestimate the
potential beneﬁts of mealtime lispro over RHI in the UK.
Conclusions
The ﬁndings of our literature review indicated that mealtime
insulin lispro is associated with short-term beneﬁts in glycaemic
control (HbA1c and postprandial glycaemic excursions) and
hypoglycaemic event rates compared with mealtime RHI, when
both are used as part of a basal–bolus regimen in T1DM.
Simulationoflong-termoutcomesbasedontheseobservations,in
a population representative of T1DM patients in the UK,
indicated that insulin lispro is likely to be associated with
improvements in life expectancy, quality-adjusted life
expectancy, time to onset of complications, complication rates
and lower direct medical costs over patients’ lifetimes compared
with RHI.
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